TheraSphere for the Treatment of Liver Metastases
收藏NIAID Data Ecosystem2026-03-06 收录
官方服务：
资源简介：
This study will evaluate Liver Progression Free Survival (PFS) and safety of TheraSphere treatment at doses of 120 Gy +/1 10% in patients at least 18 years of age diagnosed with metastatic disease to the liver that cannot be treated or is progressing following treatment with systemic or other liver-directed therapies.
创建时间：
2007-01-15
